



Winners announced for 4th Annual World ADC Awards

World ADC is pleased to announce the finalists in the 4th Annual World ADC Awards

SAN DIEGO, CA, UNITED STATES, September 22, 2017 /EINPresswire.com/ -- The [World ADC Awards](#) showcase the innovation, leadership and devotion shown by the best companies, teams and individuals in the industry.

Across 9 categories the Awards will recognise the extraordinary endeavours, teamwork and commercial acumen that has propelled the field to the forefront of cancer research today.

The 4th Annual World ADC Awards Ceremony will be taking place the evening of September 21 at the Sheraton San Diego Marina at 7.15pm

The World ADC Awards are sponsored by Abbvie (Headline Sponsor), Immunogen (Long Standing Contribution to the Field), Ambrx (Best ADC Platform Technology) and Medimmune (Best Publication 2016).

The Awardees were shortlisted from over 1600 votes cast and scientific proposals from each submission were evaluated by our Judging panel.

Fiona Mistri, Program Director, [World ADC San Diego](#) stated:

“Every year the judges are impressed with the level of innovation and scientific breakthroughs that these companies are driving. This year is no exception and we are delighted to see the calibre and quantity of entries – showing the growing momentum and advances being made within the industry.”

Jagath Reddy Junutula, Cellerent Therapeutics and judge of the Awards said:

"The World ADC Awards showcase excellence within the antibody-drug conjugate (ADC) field. This year's winners represent once again the dedication, leadership and innovation that exists in this crucial area of oncology therapeutics. These Awards shine a spotlight on these companies leading the field and as a judge once again I was delighted to see the growing momentum and progress within the field."

The 2017 winners are:

Best Platform Technology (sponsored by Ambrx)

Winner: Bicycle Therapeutics

Runner Up: Synaffix

Most Promising Clinical Candidate

Winner: ImmunoGen (Mirvetuximab soravtansine)

Runner Up: Stemcentrx (Rova-T)

Best CMO Provider

Winner: Lonza

Runner Up: BSP Pharmaceuticals

Best New Drug Developer:

Winner: Mersana

Runner Up: Heidelberg Pharma

Best CRO Provider

Winner: PPD

Runner Up: SynGene International Ltd

Best Publication 2016 (sponsored by Medimmune)

Winner: A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy.

Li JY, Perry SR, Muniz-Medina V, Wang X, Wetzel LK, Rebelatto MC, Hinrichs MJ, Bezabeh BZ, Fleming RL, Dimasi N, Feng H, Toader D, Yuan AQ, Xu L, Lin J, Gao C, Wu H, Dixit R, Osbourn JK, Coats SR.

Cancer Cell. 2016 Jan 11;29(1):117-29. doi: 10.1016/j.ccell.2015.12.008.

Runner Up: Targeted drug delivery through the traceless release of tertiary and heteroaryl amines from antibody-drug conjugates.

Staben LR1, Koenig SG1, Lehar SM1, Vandlen R1, Zhang D1, Chuh J1, Yu SF1, Ng C1, Guo J1, Liu Y1, Fourie-O'Donohue A1, Go M1, Linghu X1, Segraves NL1, Wang T2, Chen J2, Wei B1, Phillips GD1, Xu K1, Kozak KR1, Mariathasan S1, Flygare JA1, Pillow TH1.

Nat Chem. 2016 Dec;8(12):1112-1119. doi: 10.1038/nchem.2635.

Individual Input to the Field 2016

Gregory Winter

Long Standing Contribution

Jagath Reddy Junutula

For more information about the World ADC Awards visit <http://worldadc-awards.com/>

About World ADC San Diego

Focused on ADCs and crafted with the field's thought-leaders, World ADC is the industry's definitive forum for learning and networking.

About Abbvie:

Abbvie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. Together with its wholly-owned subsidiary, Pharmacyclics, Abbvie employs more than 28,000 people worldwide and markets medicines in more than 170 countries. For further information on the company and its people, portfolio and commitments, please follow @abbvie on Twitter or view careers on our Facebook or LinkedIn page.

www.abbvie.com

About Immunogen:

ImmunoGen is a clinical-stage biotechnology company that develops targeted anticancer therapeutics using its proprietary antibody-drug conjugate (ADC) technology. The Company's lead product candidate, mirvetuximab soravtansine, is a potential treatment for folate receptor α -positive ovarian cancer and other solid tumors. A number of major healthcare companies have licensed limited rights to use ImmunoGen's ADC technology to develop anticancer therapies; it is used in Roche's marketed product, Kadcyra.

www.immunogen.com

About Ambrx

Ambrx®, Inc. is a biopharmaceutical company with a mission to deliver breakthrough protein therapeutics using an expanded genetic code. Ambrx technology combines site specific conjugation with proprietary linkers, payloads and pharmacokinetic extenders

Jenny Barlow
Hanson Wade
020 3141 8700
email us here

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2017 IPD Group, Inc. All Right Reserved.